Advanced search
Publication Cover
mAbs Volume 4, 2012 - Issue 1
Submit an article Journal homepage
1,080
Views
23
CrossRef citations to date
0
Altmetric
Report

A recombinant triplebody with specificity for CD19 and HLA-DR mediates 
preferential binding to antigen double-positive cells by dual-targeting

Ingo Schubert Erlangen, Germany; Department of Biology; University of Erlangen-NurembergCorrespondence[email protected]
,
Christian Kellner Division of Stem Cell Transplantation and Immunotherapy; 2nd Medical Department; Christian-Albrechts-University; Kiel, Germany
,
Christoph Stein Department of Experimental Medicine and Immunotherapy; Institute of Applied Medical 
Engineering Helmholtz Institute; RWTH; Aachen, Germany
,
Markus Kügler MorphoSys AG; Martinsried/Planegg, Germany
,
Michael Schwenkert MorphoSys AG; Martinsried/Planegg, Germany
,
Domenica Saul Erlangen, Germany; Department of Biology; University of Erlangen-Nuremberg
,
Bernhard Stockmeyer Erlangen, Germany; Department of Internal Medicine 5 Hematology/Oncology; University of Erlangen
,
Christian Berens Erlangen, Germany; Department of Biology; University of Erlangen-Nuremberg
,
Fuat S. Oduncu Department of Hematology and Oncology; Medizinische Klinik Campus Innenstadt; Klinikum der Ludwig-Maximilians-Universität München; Munich, Germany
,
Andreas Mackensen Erlangen, Germany; Department of Internal Medicine 5 Hematology/Oncology; University of Erlangen
&
Georg H. Fey Erlangen, Germany; Department of Biology; University of Erlangen-Nuremberg
 show all
Pages 45-56 | Received 26 Sep 2011, Accepted 23 Oct 2011, Published online: 01 Jan 2012

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Todd A. Braciak, Claudia C. Roskopf, Sarah Wildenhain, Nadja C. Fenn, Christian B. Schiller, Ingo A. Schubert, Uwe Jacob, Annemarie Honegger, Christina Krupka, Marion Subklewe, Karsten Spiekermann, Karl-Peter Hopfner, Georg H. Fey, Michael Aigner, Stefan Krause, Andreas Mackensen & Fuat S. Oduncu. (2018) Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. OncoImmunology 7:9.
Read now
Ingo Schubert, Domenica Saul, Stefanie Nowecki, Andreas Mackensen, Georg H Fey & Fuat S Oduncu. (2014) A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. mAbs 6:1, pages 286-296.
Read now

Articles from other publishers (21)

Yaping Sun & Jian Xu. (2022) Emerging Antibodies in Cancer Therapy. Advanced NanoBiomed Research 3:1.
Crossref
Lukas Pekar, Katja Klausz, Michael Busch, Bernhard Valldorf, Harald Kolmar, Daniela Wesch, Hans-Heinrich Oberg, Steffen Krohn, Ammelie Svea Boje, Carina Lynn Gehlert, Lars Toleikis, Simon Krah, Tushar Gupta, Brian Rabinovich, Stefan Zielonka & Matthias Peipp. (2021) Affinity Maturation of B7-H6 Translates into Enhanced NK Cell–Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement. The Journal of Immunology 206:1, pages 225-236.
Crossref
Chungyong Han, Beom K. Choi, Seon-Hee Kim, Su-Jung Sim, Seongeun Han, Bomi Park, Yohei Tsuchiya, Masaki Takahashi, Young H. Kim, Hyeon-Seok Eom, Tetsuya Kitaguchi, Hiroshi Ueda & Byoung S. Kwon. (2020) Polymorphic Region-Specific Antibody for Evaluation of Affinity-Associated Profile of Chimeric Antigen Receptor. Molecular Therapy - Oncolytics 17, pages 293-305.
Crossref
Jules Russick, Carine Torset, Edouard Hemery & Isabelle Cremer. (2020) NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. Seminars in Immunology 48, pages 101407.
Crossref
Barbara Bassani, Denisa Baci, Matteo Gallazzi, Alessandro Poggi, Antonino Bruno & Lorenzo Mortara. (2019) Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects. Cancers 11:4, pages 461.
Crossref
Jeffrey S. MillerLewis L. Lanier. (2019) Natural Killer Cells in Cancer Immunotherapy. Annual Review of Cancer Biology 3:1, pages 77-103.
Crossref
Marta Lisowska, Aleksandra Pawlak, Justyna Kutkowska, Wojciech Hildebrand, Maciej Ugorski, Andrzej Rapak & Arkadiusz Miazek. (2018) Development of novel monoclonal antibodies to dog leukocyte antigen DR displaying direct and immune-mediated cytotoxicity toward canine lymphoma cell lines. Hematological Oncology 36:3, pages 554-560.
Crossref
Elena Grieger, Gerrit Gresch, Judith Niesen, Mira Woitok, Stefan Barth, Rainer Fischer, Rolf Fendel & Christoph Stein. (2017) Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13–ETA′ and the bispecific scFv [13xds16]. Journal of Cancer Research and Clinical Oncology 143:11, pages 2159-2170.
Crossref
Thorsten Gantke, Michael Weichel, Carmen Herbrecht, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Markus Eser, Thomas Müller, Remko Griep, Vera Molkenthin, Eugene A Zhukovsky & Martin Treder. (2017) Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells. Protein Engineering, Design and Selection 30:9, pages 673-684.
Crossref
Zachary B. Davis, Daniel A. Vallera, Jeffrey S. Miller & Martin Felices. (2017) Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Seminars in Immunology 31, pages 64-75.
Crossref
Yariv Mazor, Kris F. Sachsenmeier, Chunning Yang, Anna Hansen, Jessica Filderman, Kathy Mulgrew, Herren Wu & William F. Dall’Acqua. (2017) Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Scientific Reports 7:1.
Crossref
D. Hendriks, G. Choi, M. de Bruyn, V.R. Wiersma & E. Bremer. 2017. 289 383 .
Christian B. Schiller, Todd A. Braciak, Nadja C. Fenn, Ursula J. E. Seidel, Claudia C. Roskopf, Sarah Wildenhain, Annemarie Honegger, Ingo A. Schubert, Alexandra Schele, Kerstin Lämmermann, Georg H. Fey, Uwe Jacob, Peter Lang, Karl-Peter Hopfner & Fuat S. Oduncu. (2016) CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells. Oncotarget 7:50, pages 83392-83408.
Crossref
Claudia C. Roskopf, Todd A. Braciak, Nadja C. Fenn, Sebastian Kobold, Georg H. Fey, Karl-Peter Hopfner & Fuat S. Oduncu. (2016) Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells. Oncotarget 7:16, pages 22579-22589.
Crossref
Martin Felices, Todd R. Lenvik, Zachary B. Davis, Jeffrey S. Miller & Daniel A. Vallera. 2016. Natural Killer Cells. Natural Killer Cells 333 346 .
Claudia Arndt, Anja Feldmann, Stefanie Koristka, Marc Cartellieri, Maria Dimmel, Armin Ehninger, Gerhard Ehninger & Michael Bachmann. (2014) Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system. The Prostate 74:13, pages 1335-1346.
Crossref
Claudia C. Roskopf, Christian B. Schiller, Todd A. Braciak, Sebastian Kobold, Ingo A. Schubert, Georg H. Fey, Karl-Peter Hopfner & Fuat S. Oduncu. (2014) T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell. Oncotarget 5:15, pages 6466-6483.
Crossref
Todd A Braciak, Sarah Wildenhain, Claudia C Roskopf, Ingo A Schubert, Georg H Fey, Uwe Jacob, Karl-Peter Hopfner & Fuat S Oduncu. (2013) NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2. Journal of Translational Medicine 11:1, pages 289.
Crossref
Carmen D. Schweighofer, Armin Tuchscherer, Sabine Sperka, Thorsten Meyer, Benno Rattel, Sandra Stein, Semra Ismail, Thomas Elter, Peter Staib, Marcel Reiser & Michael Hallek. (2012) Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study. Cancer Immunology, Immunotherapy 61:12, pages 2367-2373.
Crossref
Christoph Stein, Ingo Schubert & Georg H. Fey. (2012) Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics. Antibodies 1:1, pages 88-123.
Crossref
Ingo Schubert, Christoph Stein & Georg H. Fey. (2012) Dual-Targeting for the Elimination of Cancer Cells with Increased Selectivity. Antibodies 1:1, pages 2-18.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.